Biotechnology

From Wikipedia, the free encyclopedia

 

Insulin crystals

Biotechnology is a broad area of biology, involving the use of living systems and organisms to develop or make products. Depending on the tools and applications, it often overlaps with related scientific fields. In the late 20th and early 21st centuries, biotechnology has expanded to include new and diverse sciences, such as genomics, recombinant gene techniques, applied immunology, and development of pharmaceutical therapies and diagnostic tests. The term biotechnology was first used by Karl Ereky in 1919, meaning the production of products from raw materials with the aid of living organisms.

Contents

• 1 Definition
• 2 History
• 3 Examples
  • 3.1 Medicine
  • 3.2 Agriculture
  • 3.3 Industrial
  • 3.4 Environmental
  • 3.5 Regulation
• 4 Learning
• 5 References and notes
• 6 External links

Definition

The wide concept of biotechnology encompasses a wide range of procedures for modifying living organisms according to human purposes, going back to domestication of animals, cultivation of the plants, and "improvements" to these through breeding programs that employ artificial selection and hybridization. Modern usage also includes genetic engineering as well as cell and tissue culture technologies. The American Chemical Society defines biotechnology as the application of biological organisms, systems, or processes by various industries to learning about the science of life and the improvement of the value of materials and organisms such as pharmaceuticals, crops, and livestock. Per the European Federation of Biotechnology, biotechnology is the integration of natural science and organisms, cells, parts thereof, and molecular analogues for products and services. Biotechnology is based on the basic biological sciences (e.g. molecular biology, biochemistry, cell biology, embryology, genetics, microbiology) and conversely provides methods to support and perform basic research in biology.

Biotechnology is the research and development in the laboratory using bioinformatics for exploration, extraction, exploitation and production from any living organisms and any source of biomass by means of biochemical engineering where high value-added products could be planned (reproduced by biosynthesis, for example), forecasted, formulated, developed, manufactured, and marketed for the purpose of sustainable operations (for the return from bottomless initial investment on R & D) and gaining durable patents rights (for exclusives rights for sales, and prior to this to receive national and international approval from the results on animal experiment and human experiment, especially on the pharmaceutical branch of biotechnology to prevent any undetected side-effects or safety concerns by using the products). The utilization of biological processes, organisms or systems to produce products that are anticipated to improve human lives is termed biotechnology.

By contrast, bioengineering is generally thought of as a related field that more heavily emphasizes higher systems approaches (not necessarily the altering or using of biological materials directly) for interfacing with and utilizing living things. Bioengineering is the application of the principles of engineering and natural sciences to tissues, cells and molecules. This can be considered as the use of knowledge from working with and manipulating biology to achieve a result that can improve functions in plants and animals. Relatedly, biomedical engineering is an overlapping field that often draws upon and applies biotechnology (by various definitions), especially in certain sub-fields of biomedical or chemical engineering such as tissue engineering, biopharmaceutical engineering, and genetic engineering.

History

Brewing was an early application of biotechnology.

Although not normally what first comes to mind, many forms of human-derived agriculture clearly fit the broad definition of "'utilizing a biotechnological system to make products". Indeed, the cultivation of plants may be viewed as the earliest biotechnological enterprise.

Agriculture has been theorized to have become the dominant way of producing food since the Neolithic Revolution. Through early biotechnology, the earliest farmers selected and bred the best-suited crops, having the highest yields, to produce enough food to support a growing population. As crops and fields became increasingly large and difficult to maintain, it was discovered that specific organisms and their by-products could effectively fertilize, restore nitrogen, and control pests. Throughout the history of agriculture, farmers have inadvertently altered the genetics of their crops through introducing them to new environments and breeding them with other plants — one of the first forms of biotechnology.

These processes also were included in early fermentation of beer. These processes were introduced in early Mesopotamia, Egypt, China and India, and still use the same basic biological methods. In brewing, malted grains (containing enzymes) convert starch from grains into sugar and then adding specific yeasts to produce beer. In this process, carbohydrates in the grains broke down into alcohols,e such as ethanol. Later, other cultures produced the process of lactic acid fermentation, which produced other preserved foods, such as soy sauce. Fermentation was also used in this time period to produce leavened bread. Although the process of fermentation was not fully understood until Louis Pasteur's work in 1857, it is still the first use of biotechnology to convert a food source into another form.

Before the time of Charles Darwin's work and life, animal and plant scientists had already used selective breeding. Darwin added to that body of work with his scientific observations about the ability of science to change species. These accounts contributed to Darwin's theory of natural selection.

For thousands of years, humans have used selective breeding to improve the production of crops and livestock to use them for food. In selective breeding, organisms with desirable characteristics are mated to produce offspring with the same characteristics. For example, this technique was used with corn to produce the largest and sweetest crops.

In the early twentieth century scientists gained a greater understanding of microbiology and explored ways of manufacturing specific products. In 1917, Chaim Weizmann first used a pure microbiological culture in an industrial process, that of manufacturing corn starch using Clostridium acetobutylicum, to produce acetone, which the United Kingdom desperately needed to manufacture explosives during World War I.

Biotechnology has also led to the development of antibiotics. In 1928, Alexander Fleming discovered the mold Penicillium. His work led to the purification of the antibiotic compound formed by the mold by Howard Florey, Ernst Boris Chain and Norman Heatley – to form what we today know as penicillin. In 1940, penicillin became available for medicinal use to treat bacterial infections in humans.

The field of modern biotechnology is generally thought of as having been born in 1971 when Paul Berg's (Stanford) experiments in gene splicing had early success. Herbert W. Boyer (Univ. Calif. at San Francisco) and Stanley N. Cohen (Stanford) significantly advanced the new technology in 1972 by transferring genetic material into a bacterium, such that the imported material would be reproduced. The commercial viability of a biotechnology industry was significantly expanded on June 16, 1980, when the United States Supreme Court ruled that a genetically modified microorganism could be patented in the case of Diamond v. Chakrabarty. Indian-born Ananda Chakrabarty, working for General Electric, had modified a bacterium (of the genus Pseudomonas) capable of breaking down crude oil, which he proposed to use in treating oil spills. (Chakrabarty's work did not involve gene manipulation but rather the transfer of entire organelles between strains of the Pseudomonas bacterium.

The MOSFET (metal-oxide-semiconductor field-effect transistor) was invented by Mohamed M. Atalla and Dawon Kahng in 1959. Two years later, Leland C. Clark and Champ Lyons invented the first biosensor in 1962. Biosensor MOSFETs were later developed, and they have since been widely used to measure physical, chemical, biological and environmental parameters. The first BioFET was the ion-sensitive field-effect transistor (ISFET), invented by Piet Bergveld in 1970. It is a special type of MOSFET, where the metal gate is replaced by an ion-sensitive membrane, electrolyte solution and reference electrode. The ISFET is widely used in biomedical applications, such as the detection of DNA hybridization, biomarker detection from blood, antibody detection, glucose measurement, pH sensing, and genetic technology.

By the mid-1980s, other BioFETs had been developed, including the gas sensor FET (GASFET), pressure sensor FET (PRESSFET), chemical field-effect transistor (ChemFET), reference ISFET (REFET), enzyme-modified FET (ENFET) and immunologically modified FET (IMFET).^[16] By the early 2000s, BioFETs such as the DNA field-effect transistor (DNAFET), gene-modified FET (GenFET) and cell-potential BioFET (CPFET) had been developed.

A factor influencing the biotechnology sector's success is improved intellectual property rights legislation—and enforcement—worldwide, as well as strengthened demand for medical and pharmaceutical products to cope with an ageing, and ailing, U.S. population.

Rising demand for biofuels is expected to be good news for the biotechnology sector, with the Department of Energy estimating ethanol usage could reduce U.S. petroleum-derived fuel consumption by up to 30% by 2030. The biotechnology sector has allowed the U.S. farming industry to rapidly increase its supply of corn and soybeans—the main inputs into biofuels—by developing genetically modified seeds that resist pests and drought. By increasing farm productivity, biotechnology boosts biofuel production.

Examples

A rose plant that began as cells grown in a tissue culture

Biotechnology has applications in four major industrial areas, including health care (medical), crop production and agriculture, non-food (industrial) uses of crops and other products (e.g. biodegradable plastics, vegetable oil, biofuels), and environmental uses.

For example, one application of biotechnology is the directed use of microorganisms for the manufacture of organic products (examples include beer and milk products). Another example is using naturally present bacteria by the mining industry in bioleaching. Biotechnology is also used to recycle, treat waste, clean up sites contaminated by industrial activities (bioremediation), and also to produce biological weapons.

A series of derived terms have been coined to identify several branches of biotechnology, for example:

• Bioinformatics (also called "gold biotechnology") is an interdisciplinary field that addresses biological problems using computational techniques, and makes the rapid organization as well as analysis of biological data possible. The field may also be referred to as computational biology, and can be defined as, "conceptualizing biology in terms of molecules and then applying informatics techniques to understand and organize the information associated with these molecules, on a large scale." Bioinformatics plays a key role in various areas, such as functional genomics, structural genomics, and proteomics, and forms a key component in the biotechnology and pharmaceutical sector.
• Blue biotechnology is based on the exploitation of sea resources to create products and industrial applications. This branch of biotechnology is the most used for the industries of refining and combustion principally on the production of bio-oils with photosynthetic micro-algae.
• Green biotechnology is biotechnology applied to agricultural processes. An example would be the selection and domestication of plants via micropropagation. Another example is the designing of transgenic plants to grow under specific environments in the presence (or absence) of chemicals. One hope is that green biotechnology might produce more environmentally friendly solutions than traditional industrial agriculture. An example of this is the engineering of a plant to express a pesticide, thereby ending the need of external application of pesticides. An example of this would be Bt corn. Whether or not green biotechnology products such as this are ultimately more environmentally friendly is a topic of considerable debate. It is commonly considered as the next phase of green revolution, which can be seen as a platform to eradicate world hunger by using technologies which enable the production of more fertile and resistant, towards biotic and abiotic stress, plants and ensures application of environmentally friendly fertilizers and the use of biopesticides, it is mainly focused on the development of agriculture. On the other hand, some of the uses of green biotechnology involve microorganisms to clean and reduce waste.
• Red biotechnology is the use of biotechnology in the medical and pharmaceutical industries, and health preservation. This branch involves the production of vaccines and antibiotics, regenerative therapies, creation of artificial organs and new diagnostics of diseases. As well as the development of hormones, stem cells, antibodies, siRNA and diagnostic tests.
• White biotechnology, also known as industrial biotechnology, is biotechnology applied to industrial processes. An example is the designing of an organism to produce a useful chemical. Another example is the using of enzymes as industrial catalysts to either produce valuable chemicals or destroy hazardous/polluting chemicals. White biotechnology tends to consume less in resources than traditional processes used to produce industrial goods.
• "Yellow biotechnology" refers to the use of biotechnology in food production, for example in making wine (winemaking), cheese (cheesemaking), and beer (brewing) by fermentation. It has also been used to refer to biotechnology applied to insects. This includes biotechnology-based approaches for the control of harmful insects, the characterisation and utilisation of active ingredients or genes of insects for research, or application in agriculture and medicine and various other approaches.
• Gray biotechnology is dedicated to environmental applications, and focused on the maintenance of biodiversity and the remotion of pollutants.
• Brown biotechnology is related to the management of arid lands and deserts. One application is the creation of enhanced seeds that resist extreme environmental conditions of arid regions, which is related to the innovation, creation of agriculture techniques and management of resources.
• Violet biotechnology is related to law, ethical and philosophical issues around biotechnology.
• Dark biotechnology is the color associated with bioterrorism or biological weapons and biowarfare which uses microorganisms, and toxins to cause diseases and death in humans, livestock and crops.

Medicine

In medicine, modern biotechnology has many applications in areas such as pharmaceutical drug discoveries and production, pharmacogenomics, and genetic testing (or genetic screening).

DNA microarray chip – some can do as many as a million blood tests at once

Pharmacogenomics (a combination of pharmacology and genomics) is the technology that analyses how genetic makeup affects an individual's response to drugs. Researchers in the field investigate the influence of genetic variation on drug responses in patients by correlating gene expression or single-nucleotide polymorphisms with a drug's efficacy or toxicity. The purpose of pharmacogenomics is to develop rational means to optimize drug therapy, with respect to the patients' genotype, to ensure maximum efficacy with minimal adverse effects. Such approaches promise the advent of "personalized medicine"; in which drugs and drug combinations are optimized for each individual's unique genetic makeup.

Computer-generated image of insulin hexamers highlighting the threefold symmetry, the zinc ions holding it together, and the histidine residues involved in zinc binding

Biotechnology has contributed to the discovery and manufacturing of traditional small molecule pharmaceutical drugs as well as drugs that are the product of biotechnology – biopharmaceutics. Modern biotechnology can be used to manufacture existing medicines relatively easily and cheaply. The first genetically engineered products were medicines designed to treat human diseases. To cite one example, in 1978 Genentech developed synthetic humanized insulin by joining its gene with a plasmid vector inserted into the bacterium Escherichia coli. Insulin, widely used for the treatment of diabetes, was previously extracted from the pancreas of abattoir animals (cattle or pigs). The genetically engineered bacteria are able to produce large quantities of synthetic human insulin at relatively low cost. Biotechnology has also enabled emerging therapeutics like gene therapy. The application of biotechnology to basic science (for example through the Human Genome Project) has also dramatically improved our understanding of biology and as our scientific knowledge of normal and disease biology has increased, our ability to develop new medicines to treat previously untreatable diseases has increased as well.

Genetic testing allows the genetic diagnosis of vulnerabilities to inherited diseases, and can also be used to determine a child's parentage (genetic mother and father) or in general a person's ancestry. In addition to studying chromosomes to the level of individual genes, genetic testing in a broader sense includes biochemical tests for the possible presence of genetic diseases, or mutant forms of genes associated with increased risk of developing genetic disorders. Genetic testing identifies changes in chromosomes, genes, or proteins. Most of the time, testing is used to find changes that are associated with inherited disorders. The results of a genetic test can confirm or rule out a suspected genetic condition or help determine a person's chance of developing or passing on a genetic disorder. As of 2011 several hundred genetic tests were in use. Since genetic testing may open up ethical or psychological problems, genetic testing is often accompanied by genetic counseling.

Agriculture

Genetically modified crops ("GM crops", or "biotech crops") are plants used in agriculture, the DNA of which has been modified with genetic engineering techniques. In most cases, the main aim is to introduce a new trait that does not occur naturally in the species. Biotechnology firms can contribute to future food security by improving the nutrition and viability of urban agriculture. Furthermore, the protection of intellectual property rights encourages private sector investment in agrobiotechnology.

Examples in food crops include resistance to certain pests, diseases, stressful environmental conditions, resistance to chemical treatments (e.g. resistance to a herbicide), reduction of spoilage, or improving the nutrient profile of the crop. Examples in non-food crops include production of pharmaceutical agents, biofuels, and other industrially useful goods, as well as for bioremediation.

Farmers have widely adopted GM technology. Between 1996 and 2011, the total surface area of land cultivated with GM crops had increased by a factor of 94, from 17,000 square kilometers (4,200,000 acres) to 1,600,000 km² (395 million acres). 10% of the world's crop lands were planted with GM crops in 2010. As of 2011, 11 different transgenic crops were grown commercially on 395 million acres (160 million hectares) in 29 countries such as the US, Brazil, Argentina, India, Canada, China, Paraguay, Pakistan, South Africa, Uruguay, Bolivia, Australia, Philippines, Myanmar, Burkina Faso, Mexico and Spain.

Genetically modified foods are foods produced from organisms that have had specific changes introduced into their DNA with the methods of genetic engineering. These techniques have allowed for the introduction of new crop traits as well as a far greater control over a food's genetic structure than previously afforded by methods such as selective breeding and mutation breeding. Commercial sale of genetically modified foods began in 1994, when Calgene first marketed its Flavr Savr delayed ripening tomato. To date most genetic modification of foods have primarily focused on cash crops in high demand by farmers such as soybean, corn, canola, and cotton seed oil. These have been engineered for resistance to pathogens and herbicides and better nutrient profiles. GM livestock have also been experimentally developed; in November 2013 none were available on the market, but in 2015 the FDA approved the first GM salmon for commercial production and consumption.

There is a scientific consensus that currently available food derived from GM crops poses no greater risk to human health than conventional food, but that each GM food needs to be tested on a case-by-case basis before introduction. Nonetheless, members of the public are much less likely than scientists to perceive GM foods as safe. The legal and regulatory status of GM foods varies by country, with some nations banning or restricting them, and others permitting them with widely differing degrees of regulation.

GM crops also provide a number of ecological benefits, if not used in excess. However, opponents have objected to GM crops per se on several grounds, including environmental concerns, whether food produced from GM crops is safe, whether GM crops are needed to address the world's food needs, and economic concerns raised by the fact these organisms are subject to intellectual property law.

Industrial

Industrial biotechnology (known mainly in Europe as white biotechnology) is the application of biotechnology for industrial purposes, including industrial fermentation. It includes the practice of using cells such as microorganisms, or components of cells like enzymes, to generate industrially useful products in sectors such as chemicals, food and feed, detergents, paper and pulp, textiles and biofuels. In the current decades, significant progress has been done in creating genetically modified organisms (GMOs) that enhance the diversity of applications and economical viability of industrial biotechnology. By using renewable raw materials to produce a variety of chemicals and fuels, industrial biotechnology is actively advancing towards lowering greenhouse gas emissions and moving away from a petrochemical-based economy.

Environmental

The environment can be affected by biotechnologies, both positively and adversely. Vallero and others have argued that the difference between beneficial biotechnology (e.g.bioremediation is to clean up an oil spill or hazard chemical leak) versus the adverse effects stemming from biotechnological enterprises (e.g. flow of genetic material from transgenic organisms into wild strains) can be seen as applications and implications, respectively. Cleaning up environmental wastes is an example of an application of environmental biotechnology; whereas loss of biodiversity or loss of containment of a harmful microbe are examples of environmental implications of biotechnology.

Regulation

The regulation of genetic engineering concerns approaches taken by governments to assess and manage the risks associated with the use of genetic engineering technology, and the development and release of genetically modified organisms (GMO), including genetically modified crops and genetically modified fish. There are differences in the regulation of GMOs between countries, with some of the most marked differences occurring between the US and Europe. Regulation varies in a given country depending on the intended use of the products of the genetic engineering. For example, a crop not intended for food use is generally not reviewed by authorities responsible for food safety. The European Union differentiates between approval for cultivation within the EU and approval for import and processing. While only a few GMOs have been approved for cultivation in the EU a number of GMOs have been approved for import and processing. The cultivation of GMOs has triggered a debate about the coexistence of GM and non-GM crops. Depending on the coexistence regulations, incentives for the cultivation of GM crops differ.

Learning

In 1988, after prompting from the United States Congress, the National Institute of General Medical Sciences (National Institutes of Health) (NIGMS) instituted a funding mechanism for biotechnology training. Universities nationwide compete for these funds to establish Biotechnology Training Programs (BTPs). Each successful application is generally funded for five years then must be competitively renewed. Graduate students in turn compete for acceptance into a BTP; if accepted, then stipend, tuition and health insurance support are provided for two or three years during the course of their Ph.D. thesis work. Nineteen institutions offer NIGMS supported BTPs. Biotechnology training is also offered at the undergraduate level and in community colleges.

Superfluid helium-4

From Wikipedia, the free encyclopedia

Superfluid helium-4 is the superfluid form of helium-4, an isotope of the element helium. A superfluid is a state of matter in which matter behaves like a fluid with zero viscosity. The substance, which looks like a normal liquid, flows without friction past any surface, which allows it to continue to circulate over obstructions and through pores in containers which hold it, subject only to its own inertia.

The formation of the superfluid is known to be related to the formation of a Bose–Einstein condensate. This is made obvious by the fact that superfluidity occurs in liquid helium-4 at far higher temperatures than it does in helium-3. Each atom of helium-4 is a boson particle, by virtue of its zero spin. Helium-3, however, is a fermion particle, which can form bosons only by pairing with itself at much lower temperatures, in a process similar to the electron pairing in superconductivity.

History

Known as a major facet in the study of quantum hydrodynamics and macroscopic quantum phenomena, the superfluidity effect was discovered by Pyotr Kapitsa and John F. Allen, and Don Misener in 1937. It has since been described through phenomenological and microscopic theories.

In the 1950s, Hall and Vinen performed experiments establishing the existence of quantized vortex lines in superfluid helium. In the 1960s, Rayfield and Reif established the existence of quantized vortex rings. Packard has observed the intersection of vortex lines with the free surface of the fluid, and Avenel and Varoquaux have studied the Josephson effect in superfluid helium-4. In 2006, a group at the University of Maryland visualized quantized vortices by using small tracer particles of solid hydrogen.

In the early 2000s, physicists created a Fermionic condensate from pairs of ultra-cold fermionic atoms. Under certain conditions, fermion pairs form diatomic molecules and undergo Bose–Einstein condensation. At the other limit, the fermions (most notably superconducting electrons) form Cooper pairs which also exhibit superfluidity. This work with ultra-cold atomic gases has allowed scientists to study the region in between these two extremes, known as the BEC-BCS crossover.

Supersolids may also have been discovered in 2004 by physicists at Penn State University. When helium-4 is cooled below about 200 mK under high pressures, a fraction (≈1%) of the solid appears to become superfluid. By quench cooling or lengthening the annealing time, thus increasing or decreasing the defect density respectively, it was shown, via torsional oscillator experiment, that the supersolid fraction could be made to range from 20% to completely non-existent. This suggested that the supersolid nature of helium-4 is not intrinsic to helium-4 but a property of helium-4 and disorder. Some emerging theories posit that the supersolid signal observed in helium-4 was actually an observation of either a superglass state or intrinsically superfluid grain boundaries in the helium-4 crystal.

Applications

Recently in the field of chemistry, superfluid helium-4 has been successfully used in spectroscopic techniques as a quantum solvent. Referred to as superfluid helium droplet spectroscopy (SHeDS), it is of great interest in studies of gas molecules, as a single molecule solvated in a superfluid medium allows a molecule to have effective rotational freedom, allowing it to behave similarly to how it would in the "gas" phase. Droplets of superfluid helium also have a characteristic temperature of about 0.4 K which cools the solvated molecule(s) to its ground or nearly ground rovibronic state.

Superfluids are also used in high-precision devices such as gyroscopes, which allow the measurement of some theoretically predicted gravitational effects (for an example, see Gravity Probe B).

The Infrared Astronomical Satellite IRAS, launched in January 1983 to gather infrared data was cooled by 73 kilograms of superfluid helium, maintaining a temperature of 1.6 K (−271.55 °C). When used in conjunction with helium-3, temperatures as low as 40 mK are routinely achieved in extreme low temperature experiments. The helium-3, in liquid state at 3.2 K, can be evaporated into the superfluid helium-4, where it acts as a gas due to the latter's properties as a Bose–Einstein condensate. This evaporation pulls energy from the overall system, which can be pumped out in a way completely analogous to normal refrigeration techniques.

Superfluid-helium technology is used to extend the temperature range of cryocoolers to lower temperatures. So far the limit is 1.19 K, but there is a potential to reach 0.7 K.

Properties

Superfluids, such as helium-4 below the lambda point, exhibit many unusual properties. A superfluid acts as if it were a mixture of a normal component, with all the properties of a normal fluid, and a superfluid component. The superfluid component has zero viscosity and zero entropy. Application of heat to a spot in superfluid helium results in a flow of the normal component which takes care of the heat transport at relatively high velocity (up to 20 cm/s) which leads to a very high effective thermal conductivity.

Film flow

Many ordinary liquids, like alcohol or petroleum, creep up solid walls, driven by their surface tension. Liquid helium also has this property, but, in the case of He-II, the flow of the liquid in the layer is not restricted by its viscosity but by a critical velocity which is about 20 cm/s. This is a fairly high velocity so superfluid helium can flow relatively easily up the wall of containers, over the top, and down to the same level as the surface of the liquid inside the container, in a siphon effect as illustrated in figure 4. In a container, lifted above the liquid level, it forms visible droplets as seen in figure 5. It was, however, observed, that the flow through nanoporous membrane becomes restricted if the pore diameter is less than 0.7 nm (i.e. roughly three times the classical diameter of helium atom), suggesting the unusual hydrodynamic properties of He arise at larger scale than in the classical liquid helium.

Rotation

Another fundamental property becomes visible if a superfluid is placed in a rotating container. Instead of rotating uniformly with the container, the rotating state consists of quantized vortices. That is, when the container is rotated at speeds below the first critical angular velocity, the liquid remains perfectly stationary. Once the first critical angular velocity is reached, the superfluid will form a vortex. The vortex strength is quantized, that is, a superfluid can only spin at certain "allowed" values. Rotation in a normal fluid, like water, is not quantized. If the rotation speed is increased more and more quantized vortices will be formed which arrange in nice patterns similar to the Abrikosov lattice in a superconductor.

Comparison with helium-3

Although the phenomenologies of the superfluid states of helium-4 and helium-3 are very similar, the microscopic details of the transitions are very different. Helium-4 atoms are bosons, and their superfluidity can be understood in terms of the Bose–Einstein statistics that they obey. Specifically, the superfluidity of helium-4 can be regarded as a consequence of Bose–Einstein condensation in an interacting system. On the other hand, helium-3 atoms are fermions, and the superfluid transition in this system is described by a generalization of the BCS theory of superconductivity. In it, Cooper pairing takes place between atoms rather than electrons, and the attractive interaction between them is mediated by spin fluctuations rather than phonons. A unified description of superconductivity and superfluidity is possible in terms of gauge symmetry breaking.

Macroscopic theory

Thermodynamics

Fig. 1. Phase diagram of ⁴He. In this diagram is also given the λ-line.

 

Fig. 2. Heat capacity of liquid ⁴He at saturated vapor pressure as function of the temperature. The peak at T=2.17 K marks a (second-order) phase transition.

 

Fig. 3. Temperature dependence of the relative superfluid and normal components ρ_n/ρ and ρ_s/ρ as functions of T.

Figure 1 is the phase diagram of ⁴He. It is a pressure-temperature (p-T) diagram indicating the solid and liquid regions separated by the melting curve (between the liquid and solid state) and the liquid and gas region, separated by the vapor-pressure line. This latter ends in the critical point where the difference between gas and liquid disappears. The diagram shows the remarkable property that ⁴He is liquid even at absolute zero. ⁴He is only solid at pressures above 25 bar.

Figure 1 also shows the λ-line. This is the line that separates two fluid regions in the phase diagram indicated by He-I and He-II. In the He-I region the helium behaves like a normal fluid; in the He-II region the helium is superfluid.

The name lambda-line comes from the specific heat – temperature plot which has the shape of the Greek letter λ. See figure 2, which shows a peak at 2.172 K, the so-called λ-point of ⁴He.

Below the lambda line the liquid can be described by the so-called two-fluid model. It behaves as if it consists of two components: a normal component, which behaves like a normal fluid, and a superfluid component with zero viscosity and zero entropy. The ratios of the respective densities ρ_n/ρ and ρ_s/ρ, with ρ_n (ρ_s) the density of the normal (superfluid) component, and ρ (the total density), depends on temperature and is represented in figure 3. By lowering the temperature, the fraction of the superfluid density increases from zero at T_λ to one at zero kelvins. Below 1 K the helium is almost completely superfluid.

It is possible to create density waves of the normal component (and hence of the superfluid component since ρ_n + ρ_s = constant) which are similar to ordinary sound waves. This effect is called second sound. Due to the temperature dependence of ρ_n (figure 3) these waves in ρ_n are also temperature waves.

Fig. 4. Helium II will "creep" along surfaces in order to find its own level – after a short while, the levels in the two containers will equalize. The Rollin film also covers the interior of the larger container; if it were not sealed, the helium II would creep out and escape.

 

Fig. 5. The liquid helium is in the superfluid phase. As long as it remains superfluid, it creeps up the wall of the cup as a thin film. It comes down on the outside, forming a drop which will fall into the liquid below. Another drop will form – and so on – until the cup is empty.

Superfluid hydrodynamics

The equation of motion for the superfluid component, in a somewhat simplified form, is given by Newton's law

${\displaystyle {\vec {F}}=M_{4}{\frac {\mathrm {d} {\vec {v}}_{s}}{\mathrm {d} t}}.}$

The mass M₄ is the molar mass of ⁴He, and ${\displaystyle {\vec {v}}_{s}}$ is the velocity of the superfluid component. The time derivative is the so-called hydrodynamic derivative, i.e. the rate of increase of the velocity when moving with the fluid. In the case of superfluid ⁴He in the gravitational field the force is given by

${\displaystyle {\vec {F}}=-{\vec {\nabla }}(\mu +M_{4}gz).}$

In this expression μ is the molar chemical potential, g the gravitational acceleration, and z the vertical coordinate. Thus we get

${\displaystyle M_{4}{\frac {\mathrm {d} {\vec {v}}_{s}}{\mathrm {d} t}}=-{\vec {\nabla }}(\mu +M_{4}gz).}$

(1)

Eq. (1) only holds if v_s is below a certain critical value, which usually is determined by the diameter of the flow channel.

In classical mechanics the force is often the gradient of a potential energy. Eq. (1) shows that, in the case of the superfluid component, the force contains a term due to the gradient of the chemical potential. This is the origin of the remarkable properties of He-II such as the fountain effect.

Fig. 6. Integration path for calculating μ at arbitrary p and T.

 

Fig. 7. Demonstration of the fountain pressure. The two vessels are connected by a superleak through which only the superfluid component can pass.

 

Fig. 8. Demonstration of the fountain effect. A capillary tube is “closed” at one end by a superleak and is placed into a bath of superfluid helium and then heated. The helium flows up through the tube and squirts like a fountain.

Fountain pressure

In order to rewrite Eq.(1) in more familiar form we use the general formula

${\displaystyle \mathrm {d} \mu =V_{m}\mathrm {d} p-S_{m}\mathrm {d} T.}$

(2)

Here S_m is the molar entropy and V_m the molar volume. With Eq.(2) μ(p,T) can be found by a line integration in the p-T plane. First we integrate from the origin (0,0) to (p,0), so at T =0. Next we integrate from (p,0) to (p,T), so with constant pressure (see figure 6). In the first integral dT=0 and in the second dp=0. With Eq.(2) we obtain

${\displaystyle \mu (p,T)=\mu (0,0)+\int _{0}^{p}V_{m}(p^{\prime },0)\mathrm {d} p^{\prime }-\int _{0}^{T}S_{m}(p,T^{\prime })\mathrm {d} T^{\prime }.}$

(3)

We are interested only in cases where p is small so that V_m is practically constant. So

${\displaystyle \int _{0}^{p}V_{m}(p^{\prime },0)\mathrm {d} p^{\prime }=V_{m0}p}$

(4)

where V_m0 is the molar volume of the liquid at T =0 and p =0. The other term in Eq.(3) is also written as a product of V_m0 and a quantity p_f which has the dimension of pressure

${\displaystyle \int _{0}^{T}S_{m}(p,T^{\prime })\mathrm {d} T^{\prime }=V_{m0}p_{f}.}$

(5)

The pressure p_f is called the fountain pressure. It can be calculated from the entropy of ⁴He which, in turn, can be calculated from the heat capacity. For T =T_λ the fountain pressure is equal to 0.692 bar. With a density of liquid helium of 125 kg/m³ and g = 9.8 m/s² this corresponds with a liquid-helium column of 56 meter height. So, in many experiments, the fountain pressure has a bigger effect on the motion of the superfluid helium than gravity.

With Eqs.(4) and (5), Eq.(3) obtains the form

${\displaystyle \mu (p,T)=\mu _{0}+V_{m0}(p-p_{f}).}$

(6)

Substitution of Eq.(6) in (1) gives

${\displaystyle \rho _{0}{\frac {\mathrm {d} {\vec {v}}_{s}}{\mathrm {d} t}}=-{\vec {\nabla }}(p+\rho _{0}gz-p_{f}).}$

(7)

with ρ₀ = M₄/V_m0 the density of liquid ⁴He at zero pressure and temperature.

Eq.(7) shows that the superfluid component is accelerated by gradients in the pressure and in the gravitational field, as usual, but also by a gradient in the fountain pressure.

So far Eq.(5) has only mathematical meaning, but in special experimental arrangements p_f can show up as a real pressure. Figure 7 shows two vessels both containing He-II. The left vessel is supposed to be at zero kelvins (T_l=0) and zero pressure (p_l = 0). The vessels are connected by a so-called superleak. This is a tube, filled with a very fine powder, so the flow of the normal component is blocked. However, the superfluid component can flow through this superleak without any problem (below a critical velocity of about 20 cm/s). In the steady state v_s=0 so Eq.(7) implies

${\displaystyle p_{l}+\rho _{0}gz_{l}-p_{fl}=p_{r}+\rho _{0}gz_{r}-p_{fr}}$

(8)

where the index l (r) applies to the left (right) side of the superleak. In this particular case p_l = 0, z_l = z_r, and p_fl = 0 (since T_l = 0). Consequently,

${\displaystyle 0=p_{r}-p_{fr}.}$

This means that the pressure in the right vessel is equal to the fountain pressure at T_r.

In an experiment, arranged as in figure 8, a fountain can be created. The fountain effect is used to drive the circulation of ³He in dilution refrigerators.

Fig. 9. Transport of heat by a counterflow of the normal and superfluid components of He-II

Heat transport

Figure 9 depicts a heat-conduction experiment between two temperatures T_H and T_L connected by a tube filled with He-II. When heat is applied to the hot end a pressure builds up at the hot end according to Eq.(7). This pressure drives the normal component from the hot end to the cold end according to

${\displaystyle \Delta p=-\eta _{n}Z{\dot {V}}_{n}.}$

(9)

Here η_n is the viscosity of the normal component, Z some geometrical factor, and ${\displaystyle {\dot {V}}_{n}}$ the volume flow. The normal flow is balanced by a flow of the superfluid component from the cold to the hot end. At the end sections a normal to superfluid conversion takes place and vice versa. So heat is transported, not by heat conduction, but by convection. This kind of heat transport is very effective, so the thermal conductivity of He-II is very much better than the best materials. The situation is comparable with heat pipes where heat is transported via gas–liquid conversion. The high thermal conductivity of He-II is applied for stabilizing superconducting magnets such as in the Large Hadron Collider at CERN.

Microscropic theory

Landau two-fluid approach

L. D. Landau's phenomenological and semi-microscopic theory of superfluidity of helium-4 earned him the Nobel Prize in physics, in 1962. Assuming that sound waves are the most important excitations in helium-4 at low temperatures, he showed that helium-4 flowing past a wall would not spontaneously create excitations if the flow velocity was less than the sound velocity. In this model, the sound velocity is the "critical velocity" above which superfluidity is destroyed. (Helium-4 actually has a lower flow velocity than the sound velocity, but this model is useful to illustrate the concept.) Landau also showed that the sound wave and other excitations could equilibrate with one another and flow separately from the rest of the helium-4, which is known as the "condensate".

From the momentum and flow velocity of the excitations he could then define a "normal fluid" density, which is zero at zero temperature and increases with temperature. At the so-called Lambda temperature, where the normal fluid density equals the total density, the helium-4 is no longer superfluid.

To explain the early specific heat data on superfluid helium-4, Landau posited the existence of a type of excitation he called a "roton", but as better data became available he considered that the "roton" was the same as a high momentum version of sound.

The Landau theory does not elaborate on the microscopic structure of the superfluid component of liquid helium. The first attempts to create a microscopic theory of the superfluid component itself were done by London and subsequently, Tisza. Other microscopical models have been proposed by different authors. Their main objective is to derive the form of the inter-particle potential between helium atoms in superfluid state from first principles of quantum mechanics. To date, a number of models of this kind have been proposed, including: models with vortex rings, hard-sphere models, and Gaussian cluster theories.

Vortex ring model

Landau thought that vorticity entered superfluid helium-4 by vortex sheets, but such sheets have since been shown to be unstable. Lars Onsager and, later independently, Feynman showed that vorticity enters by quantized vortex lines. They also developed the idea of quantum vortex rings. Arie Bijl in the 1940s, and Richard Feynman around 1955, developed microscopic theories for the roton, which was shortly observed with inelastic neutron experiments by Palevsky. Later on, Feynman admitted that his model gives only qualitative agreement with experiment.

Hard-sphere models

The models are based on the simplified form of the inter-particle potential between helium-4 atoms in the superfluid phase. Namely, the potential is assumed to be of the hard-sphere type. In these models the famous Landau (roton) spectrum of excitations is qualitatively reproduced.

Gaussian cluster approach

This is a two-scale approach which describes the superfluid component of liquid helium-4. It consists of two nested models linked via parametric space. The short-wavelength part describes the interior structure of the fluid element using a non-perturbative approach based on the Logarithmic Schrödinger equation; it suggests the Gaussian-like behaviour of the element's interior density and interparticle interaction potential. The long-wavelength part is the quantum many-body theory of such elements which deals with their dynamics and interactions. The approach provides a unified description of the phonon, maxon and roton excitations, and has noteworthy agreement with experiment: with one essential parameter to fit one reproduces at high accuracy the Landau roton spectrum, sound velocity and structure factor of superfluid helium-4. This model utilizes the general theory of quantum Bose liquids with logarithmic nonlinearities which is based on introducing a dissipative-type contribution to energy related to the quantum Everett–Hirschman entropy function.